Home
Live Updates
Tisagenlecleucel Yields Durable Responses in R/R Follicular Lymphoma : comparemela.com
Tisagenlecleucel Yields Durable Responses in R/R Follicular Lymphoma
Patients with relapsed/refractory follicular lymphoma experienced durable responses when treated with tisagenlecleucel (Kymriah) in the phase 2 ELARA study (NCT03568461), according to data presented at the 2023 ASH Annual Meeting.
Related Keywords
,
Stephenj Schuster ,
Margarita Louis Dreyfus Professor ,
Chronic Lymphocytic Leukemia ,
Lymphoma Clinical Care ,
Cash ,
Tisagenlecleucel ,
Follicular Lymphoma ,
Elara Study ,
Relapsed Refractory Follicular Lymphoma ,
Kymriah ,
comparemela.com © 2020. All Rights Reserved.